PCVX Vaxcyte Inc

USD 60.72 0.66 1.098901
Icon

Vaxcyte Inc (PCVX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 60.72

+0.66 (+1.10)%

USD 6.62B

0.59M

USD 74.00(+21.87%)

N/A

Icon

PCVX

Vaxcyte Inc (USD)
COMMON STOCK | NSD
USD 60.72
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 6.62B

N/A

USD 60.72

Vaxcyte Inc (PCVX) Stock Forecast

Show ratings and price targets of :
USD 74.00
(+21.87%)

Based on the Vaxcyte Inc stock forecast from 2 analysts, the average analyst target price for Vaxcyte Inc is USD 74.00 over the next 12 months. Vaxcyte Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vaxcyte Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Vaxcyte Inc’s stock price was USD 60.72. Vaxcyte Inc’s stock price has changed by -0.18% over the past week, -9.94% over the past month and +44.57% over the last year.

No recent analyst target price found for Vaxcyte Inc
No recent average analyst rating found for Vaxcyte Inc

Company Overview Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumo...Read More

https://vaxcyte.com

825 Industrial Road, San Carlos, CA, United States, 94070

254

December

USD

USA

Adjusted Closing Price for Vaxcyte Inc (PCVX)

Loading...

Unadjusted Closing Price for Vaxcyte Inc (PCVX)

Loading...

Share Trading Volume for Vaxcyte Inc Shares

Loading...

Compare Performance of Vaxcyte Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PCVX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Vaxcyte Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -0.22 (-0.06%) USD107.38B 29.93 21.06

ETFs Containing PCVX

Symbol Name PCVX's Weight Expense Ratio Price(Change) Market Cap
GERM
ETFMG Treatments Testing .. 3.71 % 0.68 % +0.43 (+2.61%) USD0.01B

Frequently Asked Questions About Vaxcyte Inc (PCVX) Stock

Based on ratings from 2 analysts Vaxcyte Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on PCVX's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for PCVX is USD 74.00 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 58.

Unfortunately we do not have enough data on PCVX's stock to indicate if its overvalued.

The last closing price of PCVX's stock was USD 60.72.

The most recent market capitalization for PCVX is USD 6.62B.

Based on targets from 2 analysts, the average taret price for PCVX is projected at USD 74.00 over the next 12 months. This means that PCVX's stock price may go up by +21.87% over the next 12 months.

Following are ETFs with the highest allocation to Vaxcyte Inc's stock :

GERM

As per our most recent records Vaxcyte Inc has 254 Employees.

Vaxcyte Inc's registered address is 825 Industrial Road, San Carlos, CA, United States, 94070. You can get more information about it from Vaxcyte Inc's website at https://vaxcyte.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...